X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (12584) 12584
Publication (1010) 1010
Newsletter (462) 462
Book Review (213) 213
Book Chapter (107) 107
Conference Proceeding (22) 22
Dissertation (22) 22
Book / eBook (21) 21
Magazine Article (10) 10
Data Set (3) 3
Reference (3) 3
Trade Publication Article (3) 3
Newspaper Article (1) 1
Presentation (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
animals (6594) 6594
male (6372) 6372
humans (5536) 5536
index medicus (4720) 4720
rats (4228) 4228
hypertension (3179) 3179
angiotensin (3098) 3098
female (3041) 3041
blood pressure - drug effects (2625) 2625
pharmacology & pharmacy (2070) 2070
angiotensin ii (1896) 1896
hypertension - drug therapy (1879) 1879
peripheral vascular disease (1873) 1873
middle aged (1757) 1757
angiotensin-ii (1754) 1754
physiology (1716) 1716
angiotensin receptor antagonists (1676) 1676
blood pressure (1577) 1577
blood-pressure (1545) 1545
rats, sprague-dawley (1538) 1538
renin-angiotensin system (1531) 1531
aged (1468) 1468
research (1455) 1455
angiotensin-converting enzyme inhibitors - therapeutic use (1437) 1437
losartan (1391) 1391
angiotensin ii - pharmacology (1361) 1361
cardiac & cardiovascular systems (1288) 1288
adult (1263) 1263
mice (1242) 1242
dose-response relationship, drug (1197) 1197
hypertension - physiopathology (1143) 1143
antihypertensive agents - therapeutic use (1132) 1132
renin-angiotensin system - drug effects (1111) 1111
tetrazoles - pharmacology (1055) 1055
rats, wistar (1030) 1030
treatment outcome (1025) 1025
drug therapy, combination (995) 995
antihypertensive agents - pharmacology (968) 968
angiotensin-converting enzyme inhibitors - administration & dosage (935) 935
heart failure (927) 927
urology & nephrology (909) 909
expression (904) 904
angiotensin-converting enzyme inhibitors - pharmacology (901) 901
oxidative stress (900) 900
drug therapy (893) 893
disease models, animal (880) 880
antihypertensive agents - administration & dosage (878) 878
risk factors (871) 871
medicine (870) 870
physiological aspects (828) 828
rodents (823) 823
time factors (807) 807
losartan - pharmacology (776) 776
angiotensin ii type 1 receptor blockers - pharmacology (755) 755
imidazoles - pharmacology (752) 752
angiotensin ii type 1 receptor blockers - therapeutic use (744) 744
health aspects (731) 731
mortality (723) 723
renin (707) 707
tetrazoles - administration & dosage (691) 691
dosage and administration (687) 687
endocrinology & metabolism (676) 676
diabetes (672) 672
heart failure - drug therapy (662) 662
tetrazoles - therapeutic use (658) 658
angiotensin ii - metabolism (655) 655
heart rate - drug effects (647) 647
renin-angiotensin system - physiology (644) 644
system (638) 638
receptors (636) 636
aldosterone (623) 623
enzymes (620) 620
research article (619) 619
care and treatment (617) 617
heart-failure (615) 615
receptor (606) 606
valsartan (605) 605
inhibition (603) 603
inflammation (591) 591
kidney - drug effects (591) 591
ace inhibitors (579) 579
angiotensin ii type 1 receptor blockers - administration & dosage (578) 578
analysis (552) 552
nitric oxide (551) 551
rats, inbred shr (542) 542
medicine, research & experimental (540) 540
nitric-oxide (540) 540
biphenyl compounds - pharmacology (534) 534
blood pressure - physiology (528) 528
angiotensin ii - antagonists & inhibitors (525) 525
angiotensin-converting enzyme (517) 517
medicine, general & internal (515) 515
fibrosis (509) 509
rat (508) 508
receptor, angiotensin, type 1 (506) 506
angiotensin ii - administration & dosage (499) 499
cardiovascular system (491) 491
benzimidazoles - pharmacology (490) 490
neurosciences (488) 488
heart (482) 482
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (12858) 12858
Japanese (86) 86
German (71) 71
French (39) 39
Russian (34) 34
Spanish (19) 19
Chinese (16) 16
Hungarian (9) 9
Portuguese (9) 9
Danish (8) 8
Polish (7) 7
Norwegian (5) 5
Ukrainian (5) 5
Italian (3) 3
Swedish (3) 3
Czech (2) 2
Hebrew (2) 2
Korean (2) 2
Bosnian (1) 1
Dutch (1) 1
Finnish (1) 1
Lithuanian (1) 1
Romanian (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


JACC: Heart Failure, ISSN 2213-1779, 07/2017, Volume 5, Issue 7, pp. 471 - 482
Journal Article
American Journal of Medicine, The, ISSN 0002-9343, 2012, Volume 125, Issue 9, pp. 882 - 887.e1
Abstract Objective Combination therapy, specifically with aspirin, cholesterol and blood pressure-lowering drugs, substantially reduces the risk of coronary... 
Internal Medicine | Adherence | Prevention | Cardiovascular disease | PERSISTENCE | ACUTE CORONARY SYNDROMES | CONVERTING ENZYME-INHIBITORS | SECONDARY PREVENTION | MEDICINE, GENERAL & INTERNAL | HEART-DISEASE | STATIN THERAPY | ACUTE MYOCARDIAL-INFARCTION | BETA-BLOCKERS | MEDICATION ADHERENCE | ARTERY-DISEASE | Drug Costs | Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage | Medication Adherence - statistics & numerical data | Cardiovascular Agents - administration & dosage | Age Factors | Drug Administration Schedule | Cardiovascular Diseases - prevention & control | Humans | Antihypertensive Agents - administration & dosage | Secondary Prevention - methods | Angiotensin-Converting Enzyme Inhibitors - administration & dosage | Aspirin - administration & dosage | Drug Prescriptions - statistics & numerical data | Self Administration | Time Factors | Anticholesteremic Agents - administration & dosage | Platelet Aggregation Inhibitors - administration & dosage | Calcium Channel Blockers - administration & dosage | Primary Prevention - methods | Sodium Chloride Symporter Inhibitors - administration & dosage | Myocardial Infarction - prevention & control | Adrenergic beta-Antagonists - administration & dosage | Angiotensin Receptor Antagonists - administration & dosage | Research | Patient compliance | Coronary heart disease | Drugs | Myocardial infarction | Aspirin | Side effects | Enzyme inhibitors | Risk reduction | Age | Statins
Journal Article
European Heart Journal, ISSN 0195-668X, 10/2015, Volume 36, Issue 38, pp. 2576 - 2584
Journal Article
Journal of the American Society of Nephrology, ISSN 1046-6673, 12/2009, Volume 20, Issue 12, pp. 2641 - 2650
Aldosterone promotes glomerular and tubular sclerosis independent of angiotensin II in animal models of diabetic nephropathy. Most human studies testing the... 
PRONE HYPERTENSIVE-RATS | VASCULAR INJURY | CONTROLLED-TRIAL | CARDIOVASCULAR OUTCOMES | ALDOSTERONE ANTAGONISM | HEART-FAILURE | RENAL OUTCOMES | UROLOGY & NEPHROLOGY | BLOOD-PRESSURE CONTROL | CHRONIC KIDNEY-DISEASE | ANTIHYPERTENSIVE TREATMENT | Angiotensin II Type 1 Receptor Blockers - adverse effects | Spironolactone - administration & dosage | Glycated Hemoglobin A - metabolism | Humans | Middle Aged | Diabetic Nephropathies - drug therapy | Hypertension - drug therapy | Male | Diabetic Nephropathies - physiopathology | Lisinopril - adverse effects | Angiotensin-Converting Enzyme Inhibitors - adverse effects | Adult | Female | Bicarbonates - blood | Blood Pressure - drug effects | Albuminuria - urine | Drug Therapy, Combination | Hypertension - urine | Spironolactone - adverse effects | Angiotensin II Type 1 Receptor Blockers - administration & dosage | Lisinopril - administration & dosage | Diabetic Nephropathies - urine | Mineralocorticoid Receptor Antagonists - administration & dosage | Double-Blind Method | Angiotensin-Converting Enzyme Inhibitors - administration & dosage | Creatinine - urine | Hypertension - physiopathology | Albuminuria - drug therapy | Losartan - adverse effects | Potassium - blood | Renin-Angiotensin System - drug effects | Losartan - administration & dosage | Index Medicus | Clinical Research
Journal Article
Hypertension, ISSN 0194-911X, 01/2018, Volume 71, Issue 1, pp. 70 - 77
Sacubitril/valsartan (LCZ696), a novel angiotensin receptor-neprilysin inhibitor, was recently approved for the treatment of heart failure with reduced... 
natriuretic peptide, neprilysin | hypertension | obesity | lipid metabolism | exercise-induced lipolysis | sacubitril/valsartan | SYSTEM | NEPRILYSIN INHIBITION | INTERSTITIAL ANGIOTENSIN-II | BRAIN NATRIURETIC PEPTIDE | HEART-FAILURE | natriuretic peptide | NORMAL-WEIGHT | neprilysin | LIPOLYSIS | INSULIN-RESISTANCE | valsartan | PERIPHERAL VASCULAR DISEASE | sacubitril | ADIPOSE-TISSUE | Angiotensin Receptor Antagonists - pharmacokinetics | Humans | Middle Aged | Obesity, Abdominal - diagnosis | Obesity, Abdominal - metabolism | Aminobutyrates - adverse effects | Hypertension - drug therapy | Male | Drug Monitoring - methods | Adipose Tissue - metabolism | Aminobutyrates - pharmacokinetics | Tetrazoles - administration & dosage | Female | Blood Pressure - drug effects | Aminobutyrates - administration & dosage | Hypertension - diagnosis | Amlodipine - administration & dosage | Double-Blind Method | Natriuretic Peptides - metabolism | Obesity, Abdominal - drug therapy | Treatment Outcome | Neprilysin - metabolism | Hypertension - metabolism | Calcium Channel Blockers - administration & dosage | Lipid Metabolism - drug effects | Neprilysin - antagonists & inhibitors | Exercise - physiology | Tetrazoles - adverse effects | Lipid Metabolism - physiology | Tetrazoles - pharmacokinetics | Angiotensin Receptor Antagonists - administration & dosage | Angiotensin Receptor Antagonists - adverse effects | Heart failure | Usage | Exercise | Valsartan | Analysis | Dosage and administration | Research | Lipid metabolism | Drug therapy | Health aspects | Index Medicus | 10036 | Original
Journal Article
Journal Article
Journal Article
Drugs, ISSN 0012-6667, 10/2016, Volume 76, Issue 16, pp. 1529 - 1550
Hypertension, the most common preventable risk factor for cardiovascular disease and death, is a growing health burden. Serious cardiovascular complications... 
Pharmacotherapy | Internal Medicine | Medicine & Public Health | Pharmacology/Toxicology | C-REACTIVE PROTEIN | CONVERTING ENZYME-INHIBITION | NITRIC-OXIDE SYNTHASE | ORAL VITAMIN-C | PHARMACOLOGY & PHARMACY | SMOOTH-MUSCLE-CELLS | ANGIOTENSIN-II | TOXICOLOGY | FLOW-MEDIATED DILATION | CENTRAL BLOOD-PRESSURE | CORONARY-ARTERY-DISEASE | ENDOTHELIUM-DEPENDENT VASODILATION | Antihypertensive Agents - pharmacology | Cerebrovascular Disorders - drug therapy | Angiotensin II Type 1 Receptor Blockers - therapeutic use | Cardiovascular Diseases - prevention & control | Humans | Angiotensin Receptor Antagonists - pharmacology | Calcium Channel Blockers - therapeutic use | Hypertension - drug therapy | Angiotensin II Type 1 Receptor Blockers - pharmacology | Angiotensin-Converting Enzyme Inhibitors - therapeutic use | Angiotensin-Converting Enzyme Inhibitors - pharmacology | Blood Pressure - drug effects | Renal Insufficiency - drug therapy | Angiotensin II Type 1 Receptor Blockers - administration & dosage | Angiotensin Receptor Antagonists - chemistry | Risk Factors | Antihypertensive Agents - therapeutic use | Angiotensin-Converting Enzyme Inhibitors - administration & dosage | Angiotensin-Converting Enzyme Inhibitors - chemistry | Heart Failure - drug therapy | Antihypertensive Agents - chemistry | Calcium Channel Blockers - administration & dosage | Calcium Channel Blockers - chemistry | Angiotensin Receptor Antagonists - therapeutic use | Angiotensin Receptor Antagonists - administration & dosage | Hypertension | Care and treatment | Angiotensin II receptor blockers | Dosage and administration | Blood pressure | Drug therapy | Cardiovascular diseases | Health aspects | Risk factors
Journal Article
EUROPEAN HEART JOURNAL, ISSN 0195-668X, 04/2017, Volume 38, Issue 15, pp. 1132 - 1143
Background Compared to heart failure patients with higher systolic blood pressure (SBP), those with lower SBP have a worse prognosis. To make matters worse,... 
Heart failure | TRIAL | AT1-receptor | NEPRILYSIN INHIBITION | CARDIAC & CARDIOVASCULAR SYSTEMS | Angiotensin | Neprilysin | Blood pressure | ENALAPRIL | Valsartan - administration & dosage | Humans | Aminobutyrates - adverse effects | Male | Death, Sudden, Cardiac - etiology | Enalapril - adverse effects | Dose-Response Relationship, Drug | Hypotension - mortality | Tetrazoles - administration & dosage | Angiotensin-Converting Enzyme Inhibitors - adverse effects | Female | Blood Pressure - drug effects | Aminobutyrates - administration & dosage | Drug Therapy, Combination | Enalapril - administration & dosage | Heart Failure - mortality | Drug Administration Schedule | Stroke Volume - physiology | Valsartan - adverse effects | Treatment Outcome | Hospitalization | Hypotension - chemically induced | Angiotensin-Converting Enzyme Inhibitors - administration & dosage | Heart Failure - drug therapy | Neprilysin - antagonists & inhibitors | Aged | Tetrazoles - adverse effects | Chronic Disease | Angiotensin Receptor Antagonists - administration & dosage | Angiotensin Receptor Antagonists - adverse effects | Clinical Research | Editor's Choice | Kardiologi | Cardiac and Cardiovascular Systems | enalapril heart failure | chronic hypotension systolic blood pressure heart failure blood pressure cardiovascular system safety ejection fraction cardiovascular death sacubitril / valsartan
Journal Article
The Laryngoscope, ISSN 0023-852X, 07/2015, Volume 125, Issue 7, pp. 1619 - 1623